MedTrace Logo

Ischemic Post-conditioning in the Treatment of Acute Ischemic Stroke

NCT06456437 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-06-13

No results posted yet for this study

Summary

Post-ischemic adaptation is a physical brain protective treatment strategy in which an ischemic event in an organ or tissue is treated and blood flow is restored, and an ischemic stimulus is given to local tissues to induce the production of anti-ischemic damage factors and reduce the damage associated with reperfusion therapy . Relevant basic studies have confirmed that post-ischemic adaptation can reduce infarct volume and promote neurological function recovery in animal models of cerebral infarction. Therefore, it may be beneficial to the recovery of neurological function in patients with acute ischemic stroke undergoing mechanical thrombus extraction.

Based on the above background, the use of a balloon to repeatedly dilate-contract at the original occlusion site after revascularization to block and restore arterial flow may be an effective cerebroprotective treatment for patients with large-vessel occlusion who undergo thrombolysis. However, can this approach be safely used in patients with acute ischemic stroke treated with thrombolysis? What is the protocol for the length of time patients can tolerate post-ischemic adaptation? The application of this method in the treatment of acute ischemic stroke will be explored in this study.

Conditions

  • Acute Ischemic Stroke
  • Large Vessel Occlusion
  • Intracranial Artery Occlusion With Cerebral Infarction
  • Endovascular Treatments

Interventions

DEVICE

Post-conditioning Balloon dilation and contraction

The balloon was filled at a pressure of no more than 4 atm at the original occlusion of the vessel to block blood flow for 2 minutes (confirmed by angiography), and then contracted to reperfuse the blood flow for 2 minutes, and the above steps were repeated 4 times to complete the in situ ischaemic post-acclimatisation intervention.

Sponsors & Collaborators

  • Ming Wei

    lead OTHER

Principal Investigators

  • Ming Wei, doctorate · Tianjin Huanhu Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2025-09-01
Completion
2025-12-31
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06456437 on ClinicalTrials.gov